Internal Reference Number: FOI_7412
Date Request Received: 07/09/2023 00:00:00
Date Request Replied To: 29/09/2023 00:00:00
This response was sent via: By Email
Request Summary: Usage of biologic and biosimilar products by Rheumatology Department
Request Category: Companies
| Question Number 1: Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs: • Abatacept [Orencia] • Adalimumab [Humira] • Adalimumab Biosimilars • Apremilast [Otezla] • Baricitinib [Olumiant] • Bimekizumab [Bimzelx] • Certolizumab [Cimzia] • Etanercept [Enbrel] • Etanercept Biosimilars • Filgotinib [Jyseleca] • Golimumab [Simponi] • Guselkumab [Tremfya] • Infliximab Biosimilars • Ixekizumab [Taltz] • Risankizumab [Skyrizi] • Rituximab [MabThera] • Rituximab Biosimilars • Sarilumab [Kevzara] • Secukinumab [Cosentyx] • Tocilizumab [Ro Actemra] • Tofacitinib [Xeljanz] • Upadacitinib [Rinvoq] • Ustekinumab [Stelara] | |
| Answer To Question 1: • Abatacept [Orencia] = 49 • Adalimumab [Humira] = 25 • Adalimumab Biosimilars = 310 • Apremilast [Otezla] = 9 • Baricitinib [Olumiant] = 65 • Bimekizumab [Bimzelx] = 0 • Certolizumab [Cimzia] = 43 • Etanercept [Enbrel] = 12 • Etanercept Biosimilars = 145 • Filgotinib [Jyseleca] = 27 • Golimumab [Simponi] = 20 • Guselkumab [Tremfya] = 13 • Infliximab Biosimilars = Split into two parts: Infliximab [Remicade] = 9 Infliximab Biosimilars = 26 • Ixekizumab [Taltz] = 41 • Risankizumab [Skyrizi] = 0 • Rituximab [MabThera] = 7 • Rituximab Biosimilars = 95 • Sarilumab [Kevzara] = <5 • Secukinumab [Cosentyx] = 19 • Tocilizumab [Ro Actemra] = 46 • Tofacitinib [Xeljanz] = 23 • Upadacitinib [Rinvoq] = 58 • Ustekinumab [Stelara] = 10 | |
| Question Number 2: Could you please provide the numbers of patients treated for Psoriatic Arthritis ONLY in the last 3 months with the following drugs: • Abatacept [Orencia] • Adalimumab [Humira] • Adalimumab Biosimilars • Apremilast [Otezla] • Bimekizumab [Bimzelx] • Certolizumab [Cimzia] • Etanercept [Enbrel] • Etanercept Biosimilars • Golimumab [Simponi] • Guselkumab [Tremfya] • Infliximab [Remicade] • Infliximab Biosimilars • Ixekizumab [Taltz] • Risankizumab [Skyrizi] • Secukinumab [Cosentyx] • Tofacitinib [Xeljanz] • Upadacitinib [Rinvoq] • Ustekinumab [Stelara] | |
| Answer To Question 2: • Abatacept [Orencia] = 0 • Adalimumab [Humira] = <5 • Adalimumab Biosimilars = 82 • Apremilast [Otezla] = 9 • Bimekizumab [Bimzelx] = 0 • Certolizumab [Cimzia] = 14 • Etanercept [Enbrel] = <5 • Etanercept Biosimilars = 29 • Golimumab [Simponi] = 7 • Guselkumab [Tremfya] = 13 • Infliximab [Remicade] = <5 • Infliximab Biosimilars = <5 • Ixekizumab [Taltz] = 40 • Risankizumab [Skyrizi] = 0 • Secukinumab [Cosentyx] = 8 • Tofacitinib [Xeljanz] = 17 • Upadacitinib [Rinvoq] = 7 • Ustekinumab [Stelara] = <5 | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
